| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jul 19, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 17,470 | $47.92 | $837,134.00 | -14.6% | |
| Jul 17, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 12,800 | $4.72 | $60,420.00 | -0.3% | |
| Jul 16, 2018 | ALKS Alkermes Plc. | Bloom Floyd E | Director | Sell | 20,000 | $43.95 | $879,024.00 | -13.5% | |
| Jul 12, 2018 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 50,000 | $41.77 | $2,088,300.00 | +1.6% | |
| Jul 12, 2018 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 15,000 | $54.50 | $817,552.00 | -0.5% | |
| Jul 11, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 14,399 | $16.77 | $241,422.27 | -6.7% | |
| Jul 11, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 30,000 | $46.89 | $1,406,600.00 | -20.0% | |
| Jul 11, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 30,000 | $46.89 | $1,406,600.00 | -20.0% | |
| Jul 9, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 3,250 | $16.46 | $53,497.92 | -3.5% | |
| Jul 9, 2018 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 15,000 | $53.61 | $804,150.00 | -1.0% | |
| Jul 6, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $87.44 | $15,738,300.00 | -0.1% | |
| Jul 6, 2018 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Commercial Officer | Sell | 30,000 | $20.00 | $600,000.00 | -100% | |
| Jul 5, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 170,000 | $86.62 | $14,725,740.00 | -0.1% | |
| Jul 3, 2018 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Legal Officer | Sell | 29,551 | $19.75 | $583,632.25 | -100% | |
| Jul 3, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $41.86 | $41,860.00 | -100% | |
| Jul 2, 2018 | PAHC Phibro Animal Health Corp | Warras Dean J | Pres Animal Health &Nutr N.a. | Sell | 10,000 | $46.38 | $463,849.60 | -73.2% | |
| Jul 2, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Patrick Gregory S | VP, Chief Financial Officer | Sell | 35,000 | $56.63 | $1,981,913.50 | -38.5% | |
| Jul 2, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 26,942 | $3.00 | $80,955.32 | -59.4% | |
| Jun 29, 2018 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 50,000 | $39.48 | $1,973,805.00 | +1.6% | |
| Jun 29, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 7,795 | $59.92 | $467,052.21 | -64.0% | |
| Jun 29, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 30,000 | $45.66 | $1,369,800.00 | -20.0% | |
| Jun 29, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 30,000 | $45.66 | $1,369,800.00 | -20.0% | |
| Jun 28, 2018 | RMTI Rockwell Medical, Inc. | Richmond David S. | 10% Owner, See Footnote 1 | Buy | 12,561 | $4.50 | $56,582.92 | +5.1% | |
| Jun 27, 2018 | CPMD Cannapharmarx, Inc. | Herick Gary J | Chief Financial Officer | Sell | 637,000 | $0.78 | $499,000.00 | -8.9% | |
| Jun 26, 2018 | AVDL Avadel Pharmaceuticals Plc | Thompson Phillandas T. | See Remarks | Buy | 10,000 | $5.77 | $57,700.00 | +12.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.